Key result
Mitral valve replacement with a bioprosthesis in patients aged 50 to 65 years resulted in a high rate of bioprosthesis dysfunction, suggesting its use should be limited.
Why the study?
The outcomes and complication rates after mitral valve replacement with bioprostheses in patients aged 50 to 65 years were not well characterized.
What are the long-term outcomes and complication rates of isolated mitral valve replacement with a bioprosthesis in patients aged 50 to 65 years?
Cohort (n=151)
What are the long-term outcomes and complication rates of isolated mitral valve replacement with a bioprosthesis in patients aged 50 to 65 years?
The high rate of bioprosthesis dysfunction in patients aged 50 to 65 years undergoing mitral valve replacement suggests that bioprosthesis use should be limited in this age group.
Answers are grounded in this paper and cite their sources.
May support limiting bioprosthesis use in this age group; leaves open optimal valve choice pending randomized data.
Between 1982 and 1990, 151 patients aged 50 to 65 years of age underwent isolated mitral valve replacement with a bioprosthesis. Overall hospital mortality was 10.6% (16/151). The total cumulative follow-up period was 527.6 patient-years with a mean of 4.34 ± 2.53 years and a range of 2 months to 10.9 years. During the follow-up period, 27 patients (5.11% per patient-year) developed bioprosthesis dysfunction of whom 26 were reoperated and one was treated medically, 4 patients had thromboembolic complications (0.75% per patient-year), one patient (0.18% per patient-year) had anticoagulant-related bleeding, and two patients (0.37% per patient-year) had a paravalvular leak (one was reoperated). Total valve-related complications were 6.44% per patient-year. Late mortality was 2.65% per patient-year (14/151). Ten-year actuarial survival was 78.5%. Freedom from bioprosthesis dysfunction was 56.6%, from thromboembolic complications 95.8%, and from all complications 49.6%. Our findings of a high rate of bioprosthesis dysfunction as well as a low rate of thromboembolic complications after mitral valve replacement with a bioprosthesis in older patients suggests that the use of bioprostheses should be limited.
No takes yet. Share an insight, caveat, or question.
Katırcıoğlu et al. (1998) conducted a cohort in Isolated mitral valve replacement (n=151). Mitral valve replacement with a bioprosthesis was evaluated on Bioprosthesis dysfunction. Mitral valve replacement with a bioprosthesis in patients aged 50 to 65 years resulted in a high rate of bioprosthesis dysfunction, suggesting its use should be limited.
Synapse has enriched 10 related papers. Consider them for comparative context: